Stifel Maintains Buy on Revolution Medicines, Raises Price Target to $230

Benzinga Newsdesk www.benzinga.com Positive 84.1%

Neg 0% Neu 0% Pos 84.1%

Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $215 to $230.